The mindset a few years ago for website development was to consider how a digital property was going to look on a mobile device. As responsive design became a reality, the logic shifted to one focused on providing a quality mobile user experience . Now, with mobile usage far surpassing computer usage for initial searches, we have to have a mobile optimized mindset as we create content for healthcare professionals.
What if you could focus your marketing plans and messaging only on the people who were actually going to buy your product or service?” This was the question posed by Clay Wilemon, DevicePharm CEO & Chief Strategy Officer, to an enthusiastic audience in San Diego during the September Device Alliance meeting.
The reality is that using predictive analytics in market research is providing a more precise way of targeting, messaging, and selling to the customers who are actually going to buy your products.
The U.S. Government states that the Affordable Care Act has three main objectives. And while these are very nice, laudable, and simple goals, they are creating paradigm shifts in the marketing and selling of medical devices.
Imagine looking at market research results and seeing that a large population of consumers wanted to pay a relatively low price for a new elective medical procedure. Just a few years ago, this would have been a cut-and-dry result leading to a lower price. However, using an advanced predictive analytics platform powered by Compellon, DevicePharm was able to dig deeper and determine that the actionable market was actually bigger with the higher price point.
“Do we really need sales reps to support medical devices?” This question has been asked by surgeons, medical device CEOs, and hospital administrators for years. Recently, however, that philosophical question moved from theory to practice in a bold move by Smith & Nephew.
To preserve editorial accuracy, let it be known to one and all that DevicePharm is not currently, nor have we ever been, an “ad agency.” Traditional or otherwise.
For a biotech company seeking to successfully launch and market a new product, especially for a company that has focused all its hopes and resources on a single new product, the stakes are very high indeed.